1 Porter, M. M., Vandervoort, A. A. & Lexell, J. Aging of human muscle: structure, function and adaptability. Scand J Med Sci Sports 5, 129-142, doi:10.1111/j.1600-0838.1995.tb00026.x (1995).
2 Volpi, E., Nazemi, R. & Fujita, S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care 7, 405-410, doi:10.1097/01.mco.0000134362.76653.b2 (2004).
3 Murgia, M. et al. Single Muscle Fiber Proteomics Reveals Fiber-Type-Specific Features of Human Muscle Aging. Cell Rep 19, 2396-2409, doi:10.1016/j.celrep.2017.05.054 (2017).
4 Carter, H. N., Chen, C. C. & Hood, D. A. Mitochondria, muscle health, and exercise with advancing age. Physiology (Bethesda) 30, 208-223, doi:10.1152/physiol.00039.2014 (2015).
5 Kamdar, F. & Garry, D. J. Dystrophin-Deficient Cardiomyopathy. J Am Coll Cardiol 67, 2533-2546, doi:10.1016/j.jacc.2016.02.081 (2016).
6 Falzarano, M. S., Scotton, C., Passarelli, C. & Ferlini, A. Duchenne Muscular Dystrophy: From Diagnosis to Therapy. Molecules 20, 18168-18184, doi:10.3390/molecules201018168 (2015).
7 Lynch, G. S., Schertzer, J. D. & Ryall, J. G. Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 113, 461-487, doi:10.1016/j.pharmthera.2006.11.004 (2007).
8 Furrer, R. & Handschin, C. Muscle Wasting Diseases: Novel Targets and Treatments. Annu Rev Pharmacol Toxicol 59, 315-339, doi:10.1146/annurev-pharmtox-010818-021041 (2019).
9 Rieu, I. et al. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J Physiol 587, 5483-5492, doi:10.1113/jphysiol.2009.178319 (2009).
10 Becker, C. et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol 3, 948-957, doi:10.1016/s2213-8587(15)00298-3 (2015).
11 Storer, T. W. et al. Effects of Testosterone Supplementation for 3 Years on Muscle Performance and Physical Function in Older Men. J Clin Endocrinol Metab 102, 583-593, doi:10.1210/jc.2016-2771 (2017).
12 Srinivas-Shankar, U. et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 95, 639-650, doi:10.1210/jc.2009-1251 (2010).
13 Grech, A., Breck, J. & Heidelbaugh, J. Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Ther Adv Drug Saf 5, 190-200, doi:10.1177/2042098614548680 (2014).
14 Rivoira, M. A., Rodriguez, V., Talamoni, G. & de Talamoni, N. T. New Perspectives in the Pharmacological Potential of Naringin in Medicine. Curr Med Chem 28, 1987-2007, doi:10.2174/0929867327666200604171351 (2021).
15 Goldwasser, J. et al. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. PLoS One 5, e12399, doi:10.1371/journal.pone.0012399 (2010).
16 Sacks, D. et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke 13, 612-632, doi:10.1177/1747493018778713 (2018).
17 Alam, M. A., Kauter, K. & Brown, L. Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, high fat diet-fed rats. Nutrients 5, 637-650, doi:10.3390/nu5030637 (2013).
18 Pu, P. et al. Naringin ameliorates metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat diet. Arch Biochem Biophys 518, 61-70, doi:10.1016/j.abb.2011.11.026 (2012).
19 Rebello, C. J. et al. Naringenin Promotes Thermogenic Gene Expression in Human White Adipose Tissue. Obesity (Silver Spring) 27, 103-111, doi:10.1002/oby.22352 (2019).
20 Goldwasser, J. et al. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol 55, 963-971, doi:10.1016/j.jhep.2011.02.011 (2011).
21 Mulvihill, E. E. et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes 58, 2198-2210, doi:10.2337/db09-0634 (2009).
22 Yu, L. M. et al. Naringenin improves mitochondrial function and reduces cardiac damage following ischemia-reperfusion injury: the role of the AMPK-SIRT3 signaling pathway. Food Funct 10, 2752-2765, doi:10.1039/c9fo00001a (2019).
23 Zygmunt, K., Faubert, B., MacNeil, J. & Tsiani, E. Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK. Biochem Biophys Res Commun 398, 178-183, doi:10.1016/j.bbrc.2010.06.048 (2010).
24 Mutlur Krishnamoorthy, R. & Carani Venkatraman, A. Polyphenols activate energy sensing network in insulin resistant models. Chem Biol Interact 275, 95-107, doi:10.1016/j.cbi.2017.07.016 (2017).
25 Bhattacharya, S. et al. Bioactive components from flowers of Sambucus nigra L. increase glucose uptake in primary porcine myotube cultures and reduce fat accumulation in Caenorhabditis elegans. J Agric Food Chem 61, 11033-11040, doi:10.1021/jf402838a (2013).
26 Ryu, D. et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci Transl Med 8, 361ra139, doi:10.1126/scitranslmed.aaf5504 (2016).
27 Misra, J., Kim, D. K. & Choi, H. S. ERRγ: a Junior Orphan with a Senior Role in Metabolism. Trends Endocrinol Metab 28, 261-272, doi:10.1016/j.tem.2016.12.005 (2017).
28 Chu, S. Transcriptional regulation by post-transcriptional modification--role of phosphorylation in Sp1 transcriptional activity. Gene 508, 1-8, doi:10.1016/j.gene.2012.07.022 (2012).
29 Tan, N. Y. & Khachigian, L. M. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 29, 2483-2488, doi:10.1128/mcb.01828-08 (2009).
30 UniProt, C. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 49, D480-D489, doi:10.1093/nar/gkaa1100 (2021).
31 Brunner, F. et al. Effects of aging on Type II muscle fibers: a systematic review of the literature. J Aging Phys Act 15, 336-348, doi:10.1123/japa.15.3.336 (2007).
32 Klitgaard, H. et al. Ageing alters the myosin heavy chain composition of single fibres from human skeletal muscle. Acta Physiol Scand 140, 55-62, doi:10.1111/j.1748-1716.1990.tb08975.x (1990).
33 Lanza, I. R., Befroy, D. E. & Kent-Braun, J. A. Age-related changes in ATP-producing pathways in human skeletal muscle in vivo. J Appl Physiol (1985) 99, 1736-1744, doi:10.1152/japplphysiol.00566.2005 (2005).
34 Short, K. R. et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A 102, 5618-5623, doi:10.1073/pnas.0501559102 (2005).
35 Yang, Z., Kuboyama, T. & Tohda, C. A Systematic Strategy for Discovering a Therapeutic Drug for Alzheimer's Disease and Its Target Molecule. Front Pharmacol 8, 340, doi:10.3389/fphar.2017.00340 (2017).
36 Vellingiri, B. et al. Understanding the Role of the Transcription Factor Sp1 in Ovarian Cancer: from Theory to Practice. Int J Mol Sci 21, doi:10.3390/ijms21031153 (2020).
37 Vizcaíno, C. et al. Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes. Biochem Pharmacol 84, 1133-1142, doi:10.1016/j.bcp.2012.08.003 (2012).
38 Muhammed, M. T. & Aki-Yalcin, E. Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem Biol Drug Des 93, 12-20, doi:10.1111/cbdd.13388 (2019).
39 Bordoli, L. et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc 4, 1-13, doi:10.1038/nprot.2008.197 (2009).
40 Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5, 725-738, doi:10.1038/nprot.2010.5 (2010).
41 Deng, H.-Y., Jia, Y. & Zhang, Y. Protein structure prediction. Acta Physica Sinica 65, doi:10.7498/aps.65.178701 (2016).
42 Yu, J., Zhou, Y., Tanaka, I. & Yao, M. Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere. Bioinformatics 26, 46-52, doi:10.1093/bioinformatics/btp599 (2010).
43 Xu, Y. et al. CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction. Nucleic Acids Res 46, W374-W379, doi:10.1093/nar/gky380 (2018).
44 Yaxia Yuan, Jianfeng Pei & Lai, L. Binding Site Detection and Druggability Prediction of Protein Targets for Structure- Based Drug Design. Current Pharmaceutical Design 19, 2326-2333 (2013).
45 Yuan, Y., Pei, J. & Lai, L. LigBuilder 2: a practical de novo drug design approach. J Chem Inf Model 51, 1083-1091, doi:10.1021/ci100350u (2011).
46 Ma, X., Meng, H. & Lai, L. Motions of Allosteric and Orthosteric Ligand-Binding Sites in Proteins are Highly Correlated. J Chem Inf Model 56, 1725-1733, doi:10.1021/acs.jcim.6b00039 (2016).